Search results for: Innovation Policy Prize
Filter search results
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in molecular diagnostics. In this…
European Union Pharmaceutical Markets: A Case for Differential Pricing?
11 August 2015
This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare….
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK. Just published is an…
New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
26 September 2016
The Office of Health Economics (OHE) and the Swedish Institute for Health Economics (IHE) publish a report evaluating the efficiency of resource allocation in cancer care across Europe. Treatments for…
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016….
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive….
New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
22 May 2017
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This research looked at the…